Rakovina Therapeutics

Rakovina Therapeutics

Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX.V: RKV), (the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the first quarter of 2024 ending March 31, and provides an update to […]

Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update Read More »

Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

FOR IMMEDIATE RELEASE  All monetary figures listed in Canadian Dollars.  May 24, 2024, Vancouver, British Columbia– Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”)

Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations Read More »

Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement 

All monetary figures listed in Canadian Dollars.  Vancouver, British Columbia, May 23, 2024 – Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds

Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement  Read More »